Government Action Archives • Page 2 of 12 • AMR.Solutions

MHRA compilation of regulatory guidance on phage products

Dear All, Attention phage developers — the UK MHRA have compiled all their regulatory guidance for phage into one convenient location! The overview webpage gives these comments: https://www.gov.uk/government/publications/regulatory-considerations-for-therapeutic-use-of-bacteriophages-in-the-uk “The MHRA has compiled a document containing all the relevant regulatory guidance pertinent to the development of phage therapeutic products. “Regulatory agencies and organisations have produced documentation

6 June 2025 No Comments

Pull incentives in Europe: Next legislative steps

Dear All (Deeply wonkish alert! Settle in! Great stuff here!): For today, we have a deep dive into the ongoing work in the EU to develop a set of realistic pull incentives using our best understanding to date of realistic choices. If the idea of Pull (and Push) is new to you, please check out

20 June 2025 No Comments

UK Pull (“Netflix-like”) pilot: STEDI-based QALY value of new antibiotics implies societal value > 10m GBP/year!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads the way on showing how it plans to provide its fair share of a global antibacterial Pull incentive (for background on Pull incentives, see this superb 5-minute video explainer). In

11 April 2022 No Comments

Ex-US new antibiotic access: Multi-year delays, even in Europe!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Post-newsletter addendum: A slide deck that summarizes the data from the paper is now available. We talked in a 22 Mar 2021 newsletter about ensuring access to new antibiotics and you should take a moment to refresh your memory of its discussions of

19 August 2021 No Comments

Italy delivers a national pull incentive (with a budget of EUR 100 million a year)!

Dear All (and with thanks to Damiano for taking the lead on this newsletter), We start the new year with good news from Rome! On Saturday 28 December 2024, the Italian Senate passed the government’s 2025 budget, giving parliament’s final approval to a financial package which includes a pull incentive for innovative antibiotics. As promised by Minister

9 January 2025 No Comments

ESCMID 2025: Science Policy Forum and Pipeline Day events

Dear All, If you are attending ESCMID Global in Vienna this year, mark your calendar for two major events. I hope to see you at both of them! First, there will be a Science Policy Forum afternoon (with networking reception) on Friday, 11 April 2025. Refined over the past two iterations of ECCMID, this event was

13 February 2025 No Comments

Sign-on Letter to Preserve Upcoming ACIP Meeting

Dear All, The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet 26-28 Feb 2025 (see links below my signature for deeper background on ACIP and how it advises on vaccine use). At least as of today, the ACIP meeting is scheduled to occur as planned: it has a full agenda that covers meningococcal vaccine, influenza

17 February 2025 No Comments

Sign-on letter encouraging AMR funding in the FY2026 US budget

Dear All, If you represent a US-based organization with an interest in AMR, there is an opportunity to sign a letter advocating for AMR-related funding in the FY2026 US Government (USG) budget. Founded in 2014, IDSA’s S-FAR (Stakeholder Forum on Antimicrobial Resistance) has been steadily coordinating messages to the USG from professional groups with an interest

12 April 2025 No Comments

Antibiotic supply chains: Challenges & Opportunities

Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact

4 May 2022 No Comments

The 6 meanings of “Lack of Access” (UNSLAP)

Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year delays in access to new antibiotics were common even in high income countries (19 Aug 2021 newsletter with YouTube discussion). But as we’ll learn today, that analysis considers only one

1 December 2024 No Comments

AMR.Solutions